Viking Therapeutics, Inc.
VKTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeViking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Valued at $4.31B, VKTX is a mid-cap name in its sector. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Market Cap
$4.31B
Beta
0.66
P/E (TTM)
—
P/E (Fwd)
-8.12
EPS (TTM)
$-4.23
EPS (Fwd)
$-4.57
ROE
-70.0%
ROA
-42.5%
Cash
$603.0M
Total Debt
$0
Free CF
-$177.4M
52W Change
15.8%
Annual Financials
Cash vs Debt
Viking Therapeutics, Inc. reports $603.0M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$177.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -70.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
VKTX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Viking Therapeutics, Inc. and its sector.